Qube Research & Technologies LTD Kymera Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

$65.7 Billion
Q3 2024

A detailed history of Qube Research & Technologies LTD transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 59,709 shares of KYMR stock, worth $2.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,709

Previous 9,386 536.15%

Holding current value

$2.3 Million

Previous $280,000 909.29%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$30.16 - $52.4 $1.52 Million - $2.64 Million	50,323 Added 536.15%	59,709 $2.83 Million
Q2 2024 Aug 14, 2024	BUY	$29.85 - $39.42 $280,172 - $369,996	9,386 New	9,386 $280,000
Q3 2023 Nov 13, 2023	BUY	$13.9 - $23.88 $63,884 - $109,752	4,596 Added 9.95%	50,785 $705,000
Q2 2023 Aug 14, 2023	BUY	$22.4 - $34.92 $846,944 - $1.32 Million	37,810 Added 451.25%	46,189 $1.06 Million
Q1 2023 May 15, 2023	SELL	$24.84 - $38.75 $462,595 - $721,641	-18,623 Reduced 68.97%	8,379 $248,000
Q4 2022 Feb 14, 2023	SELL	$19.57 - $30.92 $868,320 - $1.37 Million	-44,370 Reduced 62.17%	27,002 $673,000
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $1.49 Million - $2.45 Million	71,372 New	71,372 $1.55 Million
Q3 2021 Nov 12, 2021	SELL	$47.8 - $66.66 $628,235 - $876,112	-13,143 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$31.08 - $51.95 $408,484 - $682,778	13,143 New	13,143 $637,000
Q4 2020 Feb 16, 2021	SELL	$28.07 - $87.83 $214,960 - $672,602	-7,658 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$26.1 - $33.28 $199,873 - $254,858	7,658 New	7,658 $247,000

Others Institutions Holding KYMR

# of Institutions

181

Shares Held

64.3M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.11B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.

Account

Qube Research & Technologies LTD Kymera Therapeutics, Inc. Transaction History